Mitchell Shiffman, MD
Gastroenterology · Newport News, VANPI 1497847461
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $427,850 of the $635,014 with a category attached, or 67.4%. 32 manufacturers reported payments, led by Gilead at 28.5% of the total. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 744 payments — averaging $853.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$181K
- Intercept Pharmaceuticals, Inc.$115K
- Ipsen Biopharmaceuticals, Inc$72K
- Novo Nordisk$50K
- Madrigal Pharmaceuticals$36K
- Mirum Pharmaceuticals, Inc.$32K
- plus $149K from 26 others
Across 775 payments — averaging $5185.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$1.4M
- Madrigal Pharmaceuticals$809K
- Gilead$664K
- Takeda Pharmaceuticals U.S.A., Inc.$276K
- Ipsen Bioscience Inc.$264K
- AbbVie$226K
- plus $336K from 9 others
What the payments were for
- Consulting fees$95,29215%
- Speaking & faculty fees$427,85067%
- Travel & lodging$80,36713%
- Food & beverage$30,6565%
- Education$8490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 219 | $181,014 |
| Intercept Pharmaceuticals, Inc. | 104 | $114,564 |
| Ipsen Biopharmaceuticals, Inc | 34 | $71,652 |
| Novo Nordisk | 26 | $50,045 |
| Madrigal Pharmaceuticals | 42 | $36,350 |
| Mirum Pharmaceuticals, Inc. | 65 | $32,073 |
| Genentech USA, Inc. | 23 | $27,081 |
| AbbVie | 33 | $20,893 |
| Dova Pharmaceuticals | 16 | $20,594 |
| Eisai Inc. | 32 | $15,410 |
| Intra-sana Laboratories | 13 | $15,343 |
| Mallinckrodt Hospital Products Inc. | 16 | $13,821 |
| Ipsen Pharma SAS | 1 | $6,225 |
| Fujifilm Healthcare Americas Corporation | 13 | $5,748 |
| Shionogi Inc | 4 | $4,670 |
| Ipsen Innovation | 2 | $4,250 |
| Exelixis Inc. | 14 | $4,230 |
| AstraZeneca | 10 | $3,905 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $1,816 |
| Ipsen Bioscience Inc. | 6 | $1,811 |
| Histosonics, Inc. | 4 | $953 |
| Exact Sciences | 7 | $581 |
| Boston Scientific | 4 | $422 |
| Genentech, Inc. | 3 | $333 |
| Echosens North America, Inc. | 4 | $289 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $269 |
| Alnylam Pharmaceuticals Inc. | 2 | $231 |
| Penumbra, Inc. | 1 | $132 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| American Regent | 1 | $91 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 1 | $91 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$112,640
- Epclusa$95,600
- IQIRVO$55,951
- Wegovy$44,471
- Livdelzi$40,875
- REZDIFFRA$35,523
- Livmarli$28,119
- TECENTRIQ$23,065
- DOPTELET$20,369
- Mavyret$14,693
- LENVIMA$14,399
- TERLIVAZ$13,425
- Bylvay$9,743
- Reltone 200 Mg$7,093
- Reltone 400 Mg$7,093
- GLYCATE$6,246
- uTASWako AFP-L3$5,254
- Mulpleta$4,575
- Vemlidy$4,497
- Cabometyx$3,954
How this compares
$635,014 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 39 | $943,354 |
| LenvimaLenvatinib Mesylate | 22 | $529,222 |
| XifaxanRifaximin | 59 | $213,216 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 14 | $105,386 |
| Everolimus | 13 | $7,608 |
| Ursodiol | 28 | $5,423 |
| Tacrolimus | 12 | $3,034 |
| Mycophenolate Mofetil | 31 | $2,354 |
| Spironolactone | 104 | $1,734 |
| Lactulose | 42 | $1,145 |
| Cyproheptadine Hcl | 24 | $1,043 |
| Oxycodone Hcl | 27 | $603 |
| Furosemide | 87 | $427 |
| Prednisone | 22 | $340 |
| Pantoprazole Sodium | 34 | $303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $181,014 | $943,35439 claims |
| Eisai Inc.Lenvima | $15,410 | $529,22222 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,816 | $213,21659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Newport News
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
- Ali SiddiquiFairfax$167K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
- Kenneth JosovitzWoodbridge$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.